Josephine van Dongen

3 Updated cost-effectiveness and risk-benefit analysis 85 Scenario ∆ QALY ∆ soc- ietal cost (in mio. €) a ICER (€/ QALY) - Societal perspec- tive ∆ health- care cost (in mio. €) a ICER (€/ QALY)- Health- care payer perspec- tive Induced IS/com- plicated IS cases Induced IS: prevent- ed fatal cases Induced IS: pre- vented hospi- talized cases Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Dutch Discount rates (ef-fects (1.5%) & costs (4%)) 10 2534 (1382- 4041) 91 (69-108) 35,773 (19,780- 70,545) 127 (117- 137) 50,128 (30,299- 94,832) 58.4 / 2.8 1:1.8 (1:1.0- 1:2.8) 1:685 (1:603- 1:767) w.r.t. older age at first infection and consequently slightly lower probability of seeking medical care e 50% of 0-1 year olds were assumed to be 1-2 years old when infected 1785 (1029- 2742) 113 (90-130) 63,147 (37,271- 115,558) 148 (138- 158) 83,144 (52,799- 146,342) 58.4 / 2.8 1:1.6 (1:0.9- 1:2.6) :598 (1:528- 1:669) 75% of 0-1 year olds were assumed to be 1-2 years old when infected 1706 (984- 2608) 124 (102- 141) 72,777 (44,198- 131,290) 157 (148- 166) 92,015 (58,897- 161,918) 58.4 / 2.8 1:1.5 (1:0.8- 1:2.4) 1:528 (1:465- 1:592) w.r.t. assumed herd immunity (in baseline herd immunity was considered) No herd immunity 1690 (916- 2680) 115 (96- 131) 68,092 (39,790- 131,501) 148 (138- 158) 87,833 (53,677- 166,304) 58.4 / 2.8 1:1.7 (1:0.9- 1:2.8) 1:603 (1:527- 1:678) Lower herd immunity (*50%) 1798 (1016- 2800) 106 (85-124) 59,188 (34,260- 111,126) 143 (132- 153) 79,465 (49,224- 144,298) 58.4 / 2.8 1:1.8 (1:0.9- 1:2.8) 1:644 (1:566- 1:722) Higher herd immunity (*150%) 2017 (1212- 3045) 89 (64-109) 44,204 (24,791- 81,325) 132 (120- 143) 65,356 (41,380- 112,987) 58.4 / 2.8 1:1.8 (1:1.0- 1:2.9) 1:726 (1:640- 1:812)